中华临床免疫和变态反应杂志
中華臨床免疫和變態反應雜誌
중화림상면역화변태반응잡지
CHINESE JOURNAL OF ALLERGY & CLINICAL IMMUNOLOGY
2015年
2期
121-125
,共5页
正清风痛宁片%非甾体抗炎药%骨关节炎%Meta 分析
正清風痛寧片%非甾體抗炎藥%骨關節炎%Meta 分析
정청풍통저편%비치체항염약%골관절염%Meta 분석
Zhengqingfengtongning tablets%non-steroid anti-inflammatory drugs%osteoarthritis%meta-analysis
目的：评价正清风痛宁片联合非甾体抗炎药（non-steroid anti-inflammatory drugs，NSAIDs）治疗骨关节炎的临床疗效。方法计算机检索中国生物医学文献数据库、中国学术期刊全文数据库、中文科技期刊数据库、万方数据库、PubMed、EMbase，搜集正清风痛宁片联合 NSAIDs 与 NSAIDs 单药治疗骨关节炎的随机对照试验。中文检索词包括“正清风痛宁”、“非甾体抗炎药”、“青藤碱”、“骨关节炎”、“骨关节病”、“退行性关节炎”、“变性骨关节病”；英文检索词包括“zhengqingfengtongning”、“sinomenine”、“NSDIAs”、“osteoarthritis”。采用 Cochrance 系统评价方法评价纳入文献的质量，使用 Revman 5．2统计软件对纳入的文献进行 Meta 分析。结果共纳入4个随机对照试验，共516例患者。Meta 分析结果显示，正清风痛宁片联合 NSAIDs 显效率（65．1％比45．5％，OR ＝2．22，95％CI 为1．49～3．29，P ＜0．0001）和总有效率（93．0％比76．1％，OR ＝3．82，95％CI 为2．22～6．56，P ＜0．0001）优于单用 NSAIDs。正清风痛宁片联合 NSAIDs 不良反应发生率（19．5％）与单用 NSAIDs（11．9％）差异无统计学意义（OR ＝1．93，95％CI 为0．92～4．02，P ＝0．08）。结论正清风痛宁片联合 NSAIDs 作为一种治疗尝试，对骨关节炎治疗的进一步研究具有一定启示作用。
目的：評價正清風痛寧片聯閤非甾體抗炎藥（non-steroid anti-inflammatory drugs，NSAIDs）治療骨關節炎的臨床療效。方法計算機檢索中國生物醫學文獻數據庫、中國學術期刊全文數據庫、中文科技期刊數據庫、萬方數據庫、PubMed、EMbase，搜集正清風痛寧片聯閤 NSAIDs 與 NSAIDs 單藥治療骨關節炎的隨機對照試驗。中文檢索詞包括“正清風痛寧”、“非甾體抗炎藥”、“青籐堿”、“骨關節炎”、“骨關節病”、“退行性關節炎”、“變性骨關節病”；英文檢索詞包括“zhengqingfengtongning”、“sinomenine”、“NSDIAs”、“osteoarthritis”。採用 Cochrance 繫統評價方法評價納入文獻的質量，使用 Revman 5．2統計軟件對納入的文獻進行 Meta 分析。結果共納入4箇隨機對照試驗，共516例患者。Meta 分析結果顯示，正清風痛寧片聯閤 NSAIDs 顯效率（65．1％比45．5％，OR ＝2．22，95％CI 為1．49～3．29，P ＜0．0001）和總有效率（93．0％比76．1％，OR ＝3．82，95％CI 為2．22～6．56，P ＜0．0001）優于單用 NSAIDs。正清風痛寧片聯閤 NSAIDs 不良反應髮生率（19．5％）與單用 NSAIDs（11．9％）差異無統計學意義（OR ＝1．93，95％CI 為0．92～4．02，P ＝0．08）。結論正清風痛寧片聯閤 NSAIDs 作為一種治療嘗試，對骨關節炎治療的進一步研究具有一定啟示作用。
목적：평개정청풍통저편연합비치체항염약（non-steroid anti-inflammatory drugs，NSAIDs）치료골관절염적림상료효。방법계산궤검색중국생물의학문헌수거고、중국학술기간전문수거고、중문과기기간수거고、만방수거고、PubMed、EMbase，수집정청풍통저편연합 NSAIDs 여 NSAIDs 단약치료골관절염적수궤대조시험。중문검색사포괄“정청풍통저”、“비치체항염약”、“청등감”、“골관절염”、“골관절병”、“퇴행성관절염”、“변성골관절병”；영문검색사포괄“zhengqingfengtongning”、“sinomenine”、“NSDIAs”、“osteoarthritis”。채용 Cochrance 계통평개방법평개납입문헌적질량，사용 Revman 5．2통계연건대납입적문헌진행 Meta 분석。결과공납입4개수궤대조시험，공516례환자。Meta 분석결과현시，정청풍통저편연합 NSAIDs 현효솔（65．1％비45．5％，OR ＝2．22，95％CI 위1．49～3．29，P ＜0．0001）화총유효솔（93．0％비76．1％，OR ＝3．82，95％CI 위2．22～6．56，P ＜0．0001）우우단용 NSAIDs。정청풍통저편연합 NSAIDs 불량반응발생솔（19．5％）여단용 NSAIDs（11．9％）차이무통계학의의（OR ＝1．93，95％CI 위0．92～4．02，P ＝0．08）。결론정청풍통저편연합 NSAIDs 작위일충치료상시，대골관절염치료적진일보연구구유일정계시작용。
Objective To evaluate the clinical efficacy of Zhengqingfengtongning tablets plus non-steroid anti-inflammatory drugs (NSAIDs)for patients with osteoarthritis.Methods CBM,CNKI,VIP database, Wanfang database,PubMed and EMbase were retrieved by computer for randomized controlled trials of Zhengqingfengtongning tablets combined with NSAIDs for osteoarthritis,compared with NSAIDS only.The quality of literatures was evaluated based on the Cochrance system and meta-analyzed by using Revman5.2 version.Results A total of 4 trials involving 516 patients were included.The meta-analysis showed that the significant efficacy (65.1% vs.45.5%,OR =2.22,95% CI:1.49-3.29,P <0.000 1 )and total efficacy (93.0% vs.76.1%,OR =3.82,95%CI:2.22-6.56,P <0.000 1)of Zhengqingfengtongning tablets plus NSAIDs for osteoarthritis were better than the NSAIDs only.There was no statistical significant difference in the rate of adverse drug reaction between Zhengqingfengtongning tablets plus NSAIDs and NSAIDs only (19.5% vs.11.9%, OR = 1.93,95% CI: 0.92-4.02, P =0.08 ). Conclusion Zhengqingfengtongning tablets combined with NSAIDs has some efficacy on the treatment of osteoarthritis and has shed a light on the further research on the treatment of osteoarthritis.
